Lung MRI and impairment of diaphragmatic function in Pompe disease by Wens, Stephan C A et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Lung MRI and impairment of diaphragmatic function in Pompe disease
Wens, Stephan C A; Ciet, Pierluigi; Perez-Rovira, Adria; Logie, Karla; Salamon, Elizabeth;
Wielopolski, Piotr; de Bruijne, Marleen; Kruijshaar, Michelle E.; Tiddens, Harm A W M; van
Doorn, Pieter A.; van der Ploeg, Ans T.
Published in:
BMC Pulmonary Medicine
DOI:
10.1186/s12890-015-0058-3
Publication date:
2015
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Wens, S. C. A., Ciet, P., Perez-Rovira, A., Logie, K., Salamon, E., Wielopolski, P., ... van der Ploeg, A. T.
(2015). Lung MRI and impairment of diaphragmatic function in Pompe disease. BMC Pulmonary Medicine, 15,
[54]. https://doi.org/10.1186/s12890-015-0058-3
Download date: 03. Feb. 2020
Wens et al. BMC Pulmonary Medicine  (2015) 15:54 
DOI 10.1186/s12890-015-0058-3RESEARCH ARTICLE Open AccessLung MRI and impairment of diaphragmatic
function in Pompe disease
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Marleen de Bruijne6,8, Michelle E Kruijshaar2, Harm AWM Tiddens3,4, Pieter A van Doorn1,2 and Ans T van der Ploeg2,9*Abstract
Background: Pompe disease is a progressive metabolic myopathy. Involvement of respiratory muscles leads to
progressive pulmonary dysfunction, particularly in supine position. Diaphragmatic weakness is considered to be the
most important component. Standard spirometry is to some extent indicative but provides too little insight into
diaphragmatic dynamics. We used lung MRI to study diaphragmatic and chest-wall movements in Pompe disease.
Methods: In ten adult Pompe patients and six volunteers, we acquired two static spirometer-controlled MRI scans
during maximum inspiration and expiration. Images were manually segmented. After normalization for lung size,
changes in lung dimensions between inspiration and expiration were used for analysis; normalization was based on
the cranial-caudal length ratio (representing vertical diaphragmatic displacement), and the anterior-posterior and
left-right length ratios (representing chest-wall movements due to thoracic muscles).
Results: We observed striking dysfunction of the diaphragm in Pompe patients; in some patients the diaphragm
did not show any displacement. Patients had smaller cranial-caudal length ratios than volunteers (p < 0.001), indicating
diaphragmatic weakness. This variable strongly correlated with forced vital capacity in supine position (r = 0.88) and
postural drop (r = 0.89). While anterior-posterior length ratios also differed between patients and volunteers (p = 0.04),
left-right length ratios did not (p = 0.1).
Conclusions: MRI is an innovative tool to visualize diaphragmatic dynamics in Pompe patients and to study
chest-walland diaphragmatic movements in more detail. Our data indicate that diaphragmatic displacement
may be severely disturbed in patients with Pompe disease.
Keywords: Pompe disease, Glycogen storage disease type II, Lysosomal storage disorder, MRI, Diaphragm,
Pulmonary function, SpirometryBackground
Pompe disease (OMIM 232300: acid maltase deficiency or
glycogen storage disease type II) is an inherited progres-
sive metabolic myopathy caused by acid α-glucosidase de-
ficiency due to mutations in the acid α-glucosidase (GAA)
gene (OMIM 606800) [1,2]. Pulmonary dysfunction
caused by progressive weakness of the respiratory muscles
is a characteristic feature of the disease [1,3,4]. In patients
with the classic infantile form cardiorespiratory failure
leads to death within the first year of life [5,6]. In patients* Correspondence: a.vanderploeg@erasmusmc.nl
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unless otherwise stated.with late-onset or non-classic Pompe disease pulmonary
dysfunction progresses more slowly. The first sign of
respiratory involvement in these patients is decreased
pulmonary function in supine position, eventually ne-
cessitating respiratory support during sleep. Patients in
the end-stage of the disease require continuous respira-
tory support [7-9]. Weakness of the diaphragm–the
main respiratory muscle–is considered to be the major
cause of respiratory dysfunction in Pompe disease
[3,10]. Although pulmonary function tests (PFTs) may
be indicative of diaphragmatic weakness by showing a
difference between forced vital capacity (FVC) in sitting
and supine position–i.e. postural drop–or by a de-
creased mean inspiratory pressure (MIP), they provide
too little insight in dynamics of the diaphragm [11].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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extra relevant since enzyme replacement therapy (ERT)
has been available for Pompe disease. While several stud-
ies have shown that ERT has positive effects on skeletal
muscle function by showing stabilization or improvement
of muscle strength or the distance walked in six minutes,
the effects on lung function especially in supine position
seem to be less pronounced [7,12-16]. In an earlier study
that compared the effects of ERT on pulmonary function
in sitting and supine positions, we found that 15% of
patients were therapy resistant when pulmonary func-
tion was measured in sitting position, and that 35%
were therapy resistant when it was measured in supine
position [13]. Recent MRI sequences and image analysis
techniques make it possible to directly assess the indi-
vidual contribution of respiratory muscles–including
the diaphragm–during the breathing cycle [17-22].
The aim of the current study was to determine
whether MRI could be used as an innovative tool to gain
greater insight into the function of the diaphragm in
Pompe disease, and to correlate these data with the results
of PFTs.
Methods
Study population
All patients with Pompe disease in the Netherlands are
referred to Erasmus MC University Medical Centre
Rotterdam. For this cross-sectional pilot study we selected
ten adult patients with various degrees of respiratory dys-
function. As controls we included six age- and gender-
matched volunteers. Informed consent was obtained from
all participants. The study protocol was approved by the
Medical Ethical Committee at our hospital (Amendment 7
to protocol MEC-2007-103).
PFT
An MRI-compatible spirometer was used to standardize
lung volumes and breathing movements during the MRI
(MasterSceen Pneumo spirometer, CareFusion, Houten,
the Netherlands). Before MRI, FVC and forced expiratory
volume in one second (FEV1) were measured according to
ATS/ERS standards [23,24]. Spirometry parameters are
expressed in percentages predicted. Postural drop (ΔFVC)
was calculated as (FVCsitting-FVCsupine)/FVCsitting *100%.
An ΔFVC of more than 25% is thought to reflect dia-
phragmatic weakness [11,25]. Before MRI, a Dwyer pres-
sure gauge was used according to ATS/ERS standards to
measure maximum static inspiratory (MIP) and expiratory
pressures (MEP) [26]. Results are expressed in kilopascal
(kPa). The carbon dioxide (CO2) fraction in the expired
gas was measured with a capnograph (ms-capno, Viasys
Healthcare, Wurzberg, Germany) at maximum expiration.
In the absence of ventilation irregularities, the expiratory
CO2 approximates the arterial CO2 pressure. A daytimeexpiratory CO2 over 6.0 kPa suggests hypercapnia and
chronic alveolar hypoventilation [27].
MRI and imaging analysis
Scanning was performed with a 3T GE Signa 750 MRI
(General Electric Healthcare, Milwaukee, USA) using the
whole-body coil for radio-frequency excitation and a 32-
channel torso coil for signal reception. First, a 3-plane
localizer was performed during a maximum inspiratory
movement (i.e. a five-second breath-hold scan); all sub-
sequent volumes imaged were based on this localizer.
Second, shimming was performed on this localizer, and
shim settings were maintained throughout scanning. To
evaluate changes in lung shape and volume, two static
scans were acquired. These use two 12-second breath-
hold scans covering the entire thoracic region acquired
at end-inspiration and end-expiration in a 3D RF-spoiled
gradient echo sequence with TR/TE = 1/0.5 ms, flip
angle 2°, sagittal volume acquisition with 3 mm slice thick-
ness, 1.5 mm slice separation between slices and planar
pixel resolution between 1.4x1.4 and 1.5x1.5 mm2. Overall
acquisition time per patient was 20 minutes.
Each lung was segmented manually at inspiration and
expiration using 3D Slicer (http://www.slicer.org), with
segmentation being performed every second slice in the
axial plane [28]. A full 3D segmentation was recon-
structed by interpolating the individual segmentation
slices in the cranial-caudal axis. Using the 3D lung seg-
mentations, the length and volume of each independent
lung was estimated along the main axes of the MRI acqui-
sition (cranial-caudal, anterior-posterior and left-right). To
cope for variations in lung size due to inter-subject ana-
tomical variations, each length at maximum inspiration
was divided by the corresponding length at maximum
expiration. Therefore the normalised value is a rate of
length increase compared with the expiration point (e.g. a
ratio of 1.2 would mean an increase of 20% in length). Be-
cause of the assumption that the chest-wall is responsible
for changes in volume in the anterior-posterior and left-
right directions, and the diaphragm expands the lung in
the cranial-caudal directions, it is possible to study the
contributions to volume changes of the chest-wall and the
diaphragm individually.
Statistical analysis
Data were analyzed using SPSS version 21 (SPSS, Chicago,
IL, USA) and are presented as medians with ranges, or as
numbers with percentages. The Mann-Whitney test was
used to analyze differences in PFT results and MRI
findings between patients and volunteers. The Spearman’s
correlation coefficient (r) was used to calculate the rela-
tionship between PFT outcomes and MRI results in
Pompe patients. A p-value <0.05 was considered statisti-
cally significant.
Table 1 Patient characteristics and PFT results in patients
and volunteers
Patients Volunteers P-value
Age (years) 46 (32-66) 43 (27-55) 0.25
Gender, (% males) 5 (50) 3 (50) 1.0
Height (cm) 178 (154-196) 177 (175-190) 0.39
Weight (kg) 73 (61-88) 85 (65-94) 0.13
BMI (kg/m2) 23.4 (20.6-25.4) 24.9 (21-25.7) 0.18
Duration of the disease (years) 16 (9-30) - -
Duration of ERT (years) 5.5 (0-7) - -
Wheelchair-dependent (%) 1 (10) 0 (0) 0.79
Ventilator-dependent (%) 3 (30) 0 (0) 0.37
Pulmonary function test
FVCsitting (%) 60 (45-84) 102 (92-111) 0.001
FVCsupine (%) 43 (27-70) 102 (87-113) 0.001
ΔFVC (%)a 33 (11-44) 0 (0-10) 0.001
FEV1 sitting (l/s) 59 (42-80) 98 (85-117) 0.001
FEV1 supine (l/s) 40 (30-63) 91 (76-112) 0.001
MIP (kPa) 6.9 (3.9-8.3) 8.6 (6.4-11.8) 0.07
MEP (kPa) 10.0 (6.4-11.8) 12.5 (10.3-14.2) 0.02
Continuous variables are expressed as median and range, categorical variables
as number and percentage. BMI = body mass index, ERT = enzyme replacement
therapy, FVC = forced vital capacity, FEV1 = forced expiratory volume in one
second, MIP =maximum static inspiratory pressure, MEP =maximum static
expiratory pressure.
aΔFVC is calculated as (FVCsitting-FVCsupine)/FVCsitting x 100%.
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Study population
Table 1 shows the characteristics of the Pompe patients
and the volunteers. All Pompe patients had an acid
alpha-glucosidase deficiency and all patients carried the
common mutation c.-32-13T > G in one GAA allele and
a second pathogenic mutation in the second allele. In
five patients this second pathogenic mutation was
c.525delT, in two patients c.1548G > A, and the other
three patients carried a different second mutation. None
of the patients was currently smoking and two patientsFigure 1 Line-up during the MRI Patients were placed in supine position i
above the head.had smoked in the past. None of the patients or volunteers
had co-morbidities that could influence the function of
the diaphragm.PFT
Table 1 shows PFT in sitting and supine positions. In both
these positions, patients had lower median values for FVC
and FEV1 than healthy volunteers did (p = 0.001). The
median ΔFVC was higher in Pompe patients (p = 0.001).
The median MEP was lower in patients (10.0 kPa) than in
volunteers (12.5 kPa, p = 0.02). The median MIP showed a
trend towards a lower median value for the patients (6.9
kPa) relative to the healthy volunteers (8.6 kPa, p = 0.07).
Three patients had a expiratory CO2 fraction over 6.0 kPa
and two of these patients were ventilator-dependent.MRI
Figure 1 shows the line-up during the MRI. Participants
were placed in supine position with the MRI-compatible
spirometer positioned above them. Figure 2 shows cor-
onal slices through the carina for the breath-hold scans
with the corresponding color plots of a Pompe patient
and a volunteer. In the Pompe patient there was hardly
any displacement of the diaphragm. Additional file 1 in
the online data supplement shows the color plots of each
individual subject and Additional files 2 and 3 demon-
strate two examples of dynamic MRI scans in a healthy
volunteer and a patient with Pompe disease.
Figure 3 shows the changes per individual in the three
chest-cage directions between inspiration and expiration.
In volunteers, the main contributor to the changes in
lung volume was the diaphragm (white bars). In most
Pompe patients, these changes were due mainly to the
thoracic muscles (grey and black bars), but, as Figure 3
shows, these patients had a large variety in diaphragmatic
and chest-wall movements. The median cranial-caudal
length change, representing diaphragmatic displacement
before normalization for lung size, was 82 mm (range 46-n the MRI scanner with an MRI-compatible spirometer positioned just
Figure 2 MR images and color maps at maximum inspiration and expiration MR images during 12-second breath-holds in inspiration and expiration
in a patient with Pompe disease and a healthy volunteer. The color maps represent the thickness of the segmentation in the anterior-posterior axis
(red being the thickest and blue being the thinnest). Note the limited increase in vertical length in the Pompe patient relative to the increase in the
healthy volunteer.
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tients (p = 0.002). The median anterior-posterior length
change was 37 mm in volunteers (range 25-42 mm) and 18
mm (range 13-31 mm) in patients (p = 0.006); the median
left-right length change was 24 mm in volunteers (range
21-34 mm) and 17 mm (10-26 mm) in patients (p = 0.02).
Figure 4 shows the different length ratios after
normalization for lung size. The cranial-caudal length
ratio between inspiration and expiration (representing
diaphragmatic displacement) was lower in Pompe pa-
tients (median 1.35, range 1.07-1.64) than in volunteersFigure 3 Ratios between inspiration and expiration in three directions for
inspiration and expiration in the cranial-caudal direction (white bars), anter
are shown for individual patients and volunteers. Volunteers are numbered 1
median length during inspiration by the median length during expiration for(median 1.82, range 1.66-2.08) (p = 0.001). While the
anterior-posterior length ratio was also lower in patients
(median 1.40, range 1.20-1.58) than in volunteers (me-
dian 1.59, range 1.42-1.71) (p = 0.04), the left-right
length ratio did not differ significantly between patients
(median 1.35, range 1.20-1.56) and volunteers (median
1.41, range 1.36-1.58) (p = 0.1). In the three Pompe pa-
tients who were ventilator-dependent the cranial-caudal
length ratio was lower than in the other Pompe patients
(median 1.22 versus 1.43, p = 0.02). These ventilator-
dependent patients had a longer duration of the diseasepatients and volunteers measured with MRI. The length ratios between
ior-posterior direction (black bars) and left-right direction (grey bars)
to 6 and patients 7 to 16. The length ratios are calculated by dividing the
each axis.
Figure 4 Median ratios between inspiration and expiration in three
directions for both groups. This figure shows the same ratios as Figure 2,
but now for the groups of Pompe patients and volunteers. The box plots
represent the median with the range. The Mann-Whitney test was used
to calculate the difference in each direction between patients
and volunteers.
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ation between the cranial-caudal length ratio and the
duration of ERT.
Correlation between PFT and MRI
As Figure 5 shows, ΔFVC and FVC supine were strongly
correlated with the cranial-caudal length ratio (r = 0.89
and r = 0.88, p < 0.001) in Pompe patients, but there
were no correlation between MIP and the cranial-caudal
length ratio (r = 0.32, p = 0.37), MEP and cranial-caudal
length ratio (r = 0.23, p = 0.53), or FVC sitting and
cranial-caudal length ratio (r = 0.46, p = 0.18). The only
significant correlation regarding the anterior-posterior
length ratio was with FVC supine (r = 0.74, p = 0.02).
Discussion
Our study shows that MRI can be used as an innovative
tool to gain greater insight into involvement of the dia-
phragm in Pompe disease. It was demonstrated that the
diaphragmatic function is severely impaired and in some
patients there was even hardly any displacement of theFigure 5 Correlation between cranial-caudal length ratios and FVC supine
triangles volunteers. Spearman’s correlation coefficient (r) was used to calcu
in supine position, the postural drop (ΔFVC) and MIP. As these calculation
excluded for these analyses. FVC = forced vital capacity, MIP = maximumdiaphragm. To a lesser extent, movement of the anterior
chest-wall was reduced. Our results suggest that dia-
phragmatic displacement measured with MRI is strongly
correlated with the postural drop and FVC in supine
position measured with common spirometry.
Decreased pulmonary function is an important feature
of Pompe disease. Ten or 15 years after onset, half of the
adult patients with Pompe disease require ventilator assist-
ance. The main cause of death in this group of patients is
respiratory failure, a process in which dysfunction of the
diaphragm is considered to play an important role [8,9,29].
Our MRI study suggests that the function of the dia-
phragm in Pompe disease is more impaired than that of
the thoracic musculature. It is not clear how and why the
diaphragm muscles are more severely affected than the
other respiratory muscles. Our study supports a recent
study describing atrophy of the diaphragm and reduced
lung height on static MRI and computed tomography
scans in patients with Pompe disease. In this latter study
semi-quantitative scoring scales were used, and computed
tomography was used to measure lung height in one
direction [30]. In our study MRI was performed under
spirometry control and lung-shape variations were
quantified in three directions. This enabled us to show
that the cranial-caudal movement related to diaphrag-
matic function in patients with Pompe disease is im-
paired more than the anterior-posterior motions of
the anterior chest-wall. Similarly, the correlation we
found between ΔFVC and FVC in supine position and
our MRI results suggest that both these parameters
might be used as an indirect tool for determining dia-
phragmatic function, with the advantage that MRI also
visualizes diaphragmatic and chest-wall movements.
A striking finding in our study was that displacement
of the diaphragm was extremely impaired in some of the
patients, while still residual pulmonary function in supine
position was measurable. This could have important con-
sequences when therapy comes in place and might explain(A), postural drop (B) and MIP (C). The dots represent patients and the
late the correlation between the cranial-caudal length ratio versus FVC
s were performed only in the Pompe patients, the volunteers were
static inspiratory pressure.
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responds poorly to ERT in some of the Pompe patients.
Therefore, more studies are required to investigate at what
stage the diaphragm and other respiratory muscles be-
come affected in Pompe disease; especially since it has
been shown that response to ERT is better in patients who
are less severely affected [3,13,31]. Another intriguing
question is how MIP and MEP relate to diaphragmatic
weakness. It has been hypothesized that these parameters
might be better predictors for diaphragmatic weakness
than FVC in supine position [30]. Our study implied a
weak correlation between MIP or MEP and diaphragmatic
displacement. A possible explanation could be that MIP
reflects both the strength of the diaphragm and other
inspiratory muscles, while the cranial-caudal length ra-
tio only reflects diaphragmatic displacement. In an earl-
ier study we found a positive correlation between FVC
in upright position and MIP an MEP [3]. Larger studies
are required to explore this relationship in more depth.
Comparison of diaphragmatic involvement in patients
with Pompe disease to those with other neuromuscular
disorders such as Duchenne Muscular Dystrophy might
provide insight whether onset and the extend of dia-
phragmatic involvement is disease specific.
A limitation of our pilot study is that we selected a
relatively small number of adult Pompe patients with
variable degrees of respiratory dysfunction (FVC in supine
position: 27 to 70% of normal). This subset of patients may
not be fully representative for the total group of Pompe pa-
tients. In subsequent studies also patients with normal or
close to normal respiratory function need to be studied to
get more insight at what stage of the disease the diaphragm
becomes affected. The use of MRI to evaluate diaphrag-
matic and chest-wall movements has some limitations.
Contraindications such as metal implants, invasive ventila-
tion and claustrophobia make it impossible to scan certain
patients. Moreover, patients need to be able to perform
spirometry in supine position. In next studies it might also
be considered to include other techniques to measure lung
and respiratory muscle function in addition to spirometry
such as sniff nasal inspiratory pressures, transdiaphrag-
matic pressures or transdiaphragmatic twitch pressures
[32]. Prigent et al. showed that transdiaphragmatic pres-
sures and transdiaphragmatic twitch pressures correlated
well with all spirometry volumes and non-invasive max-
imal pressures in adult patients with Pompe disease [33].
Whether transdiaphragmatic pressure measurements show
a better correlation with the cranial-caudal length ratio
measured with lung MRI than with spirometry data needs
further investigation.
Conclusions
MRI appears to be an innovative tool to visualize dia-
phragmatic dynamics in Pompe patients and to studychest-wall and diaphragmatic movements in more detail.
Our data indicate that diaphragmatic displacement can
be very severely impaired in patients with Pompe disease
and might explain why FVC responds poorly to ERT in
some of the patients. As MRI adds detailed dynamic and
structural information to data obtained by pulmonary
function tests, particularly of the diaphragm, it may
serve as a valuable tool in providing new insights in
when the diaphragm starts to be involved in the disease
process and on its responsiveness to therapy. It may also
serve as a prognostic tool. More research is warranted to
explore these topics.
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Additional file 1: Color maps made at maximum inspiration and
expiration.
Additional file 2: Dynamic MRI in a Pompe patient during an FEV1
measurement.
Additional file 3: Dynamic MRI in a healthy volunteer during an
FEV1 measurement.
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